On Friday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) was -14.14% down from the session before settling in for the closing price of $11.88. A 52-week range for ARQT has been $1.76 – $15.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 303.42% over the past five years. When this article was written, the company’s average yearly earnings per share was at 34.21%. With a float of $97.38 million, this company’s outstanding shares have now reached $114.97 million.
Let’s look at the performance matrix of the company that is accounted for 296 employees.
Arcutis Biotherapeutics Inc (ARQT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcutis Biotherapeutics Inc stocks. The insider ownership of Arcutis Biotherapeutics Inc is 15.30%, while institutional ownership is 84.08%. The most recent insider transaction that took place on Mar 04 ’24, was worth 199,994. In this transaction Director of this company bought 21,052 shares at a rate of $9.50, taking the stock ownership to the 8,785,284 shares. Before that another transaction happened on Mar 04 ’24, when Company’s insider sold 14,903 for $11.12, making the entire transaction worth $165,739. This insider now owns 874,533 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.50 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
You can see what Arcutis Biotherapeutics Inc (ARQT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.80.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 3.72 million, a negative change from its year-to-date volume of 4.91 million. As of the previous 9 days, the stock’s Stochastic %D was 57.44%. Additionally, its Average True Range was 1.00.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 73.97%, which indicates a significant increase from 27.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.57% in the past 14 days, which was lower than the 105.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.55, while its 200-day Moving Average is $6.49. Nevertheless, the first resistance level for the watch stands at $11.38 in the near term. At $12.56, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.34. If the price goes on to break the first support level at $9.42, it is likely to go to the next support level at $8.64. The third support level lies at $7.46 if the price breaches the second support level.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are 96,813K outstanding shares of the company, which has a market capitalization of 1.17 billion. As of now, sales total 59,610 K while income totals -262,140 K. Its latest quarter income was 13,530 K while its last quarter net income were -66,280 K.
